iShares Neuroscience and Healthcare ETF (IBRN)

NYSEARCA: IBRN · Real-Time Price · USD
26.05
+0.54 (2.10%)
Sep 5, 2025, 12:22 PM - Market open
2.10%
Assets$3.78M
Expense Ratio0.47%
PE Ratio16.14
Shares Out150,000
Dividend (ttm)$0.10
Dividend Yield0.39%
Ex-Dividend DateDec 17, 2024
Payout FrequencyAnnual
Payout Ratio6.40%
Volume52
Openn/a
Previous Close25.51
Day's Rangen/a
52-Week Low17.86
52-Week High28.74
Beta0.71
Holdings63
Inception DateAug 24, 2022

About IBRN

Fund Home Page

The iShares Neuroscience and Healthcare ETF (IBRN) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market cap-weighted index that provides global equity exposure to companies that are positioned to benefit from neuroscience advancements. The index may hold securities from large- to small-cap. IBRN was launched on Aug 24, 2022 and is issued by BlackRock.

Asset Class Equity
Category Health
Region Global
Stock Exchange NYSEARCA
Ticker Symbol IBRN
ETF Provider BlackRock
Index Tracked NYSE FactSet Global Neuro Biopharma and MedTech Index

Top 10 Holdings

42.71% of assets
NameSymbolWeight
Supernus Pharmaceuticals, Inc.SUPN5.01%
argenx SEARGX4.63%
Xenon Pharmaceuticals Inc.XENE4.61%
ACADIA Pharmaceuticals Inc.ACAD4.40%
SK Biopharmaceuticals Co., Ltd.3260304.26%
Neurocrine Biosciences, Inc.NBIX4.08%
PTC Therapeutics, Inc.PTCT4.02%
Biogen Inc.BIIB4.00%
Denali Therapeutics Inc.DNLI3.91%
Scholar Rock Holding CorporationSRRK3.79%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Dec 17, 2024$0.10114Dec 20, 2024
Dec 20, 2023$0.0063Dec 27, 2023
Jun 7, 2023$0.00824Jun 13, 2023
Full Dividend History

Performance

IBRN had a total return of 3.41% in the past year, including dividends. Since the fund's inception, the average annual return has been 0.54%.

News

Why Now Could Be The Time To Consider Neuroscience Investments

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...

3 years ago - Seeking Alpha